Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Here’s What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped down prior to trading on Thursday . The stock had previously closed at $12.34, but opened at $11.86. Sysmex shares last traded at $11.88, with a volume of 497 shares traded.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised shares of Sysmex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 18th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Sysmex has a consensus rating of “Hold”.

Sysmex Trading Down 0.6%

The business’s 50 day moving average price is $10.19 and its two-hundred day moving average price is $9.30. The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $7.58 billion, a price-to-earnings ratio of 28.68 and a beta of 1.05.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings results on Friday, August 7th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.02. The company had revenue of $825.85 million for the quarter, compared to analyst estimates of $741.67 million. Sysmex had a net margin of 7.62% and a return on equity of 7.87%. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. On average, equities analysts predict that Sysmex Corporation ADR will post 0.38 earnings per share for the current fiscal year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.